Drug-Induced Psychopathologies: How Psychoactive Substances Mimic Mental Disorders

Rashee Kapoor
CMR University

I. INTRODUCTION

Substance use and mental disorders often appear confusingly similar because both influence the same biological systems that allow us to think clearly, feel emotions, stay focused, and interpret reality correctly. Many people assume that drugs simply cause a "high," but in reality, they push the brain into extreme states that resemble real psychiatric illnesses. For example, when someone uses high doses of methamphetamine, their heightened paranoia and hallucinations look exactly like schizophrenia. When a person suddenly stops drinking alcohol after drinking heavily for years, the intense shaking, fear, and panic may look indistinguishable from an anxiety disorder. The DSM-5-TR attempts to help clinicians by creating a category called "substance/medication-induced mental disorders," which explains that symptoms should start during intoxication or withdrawal and should reduce after the substance leaves the body (American Psychiatric Association, 2022). Despite these guidelines, real-life situations are much more complex. Many patients do not know or remember exactly when symptoms started, and some may hide their drug use due to fear of judgment. As a result, drug-induced conditions are often misdiagnosed as primary mental illnesses, and people may be treated with medications they do not actually need. Understanding how and why drugs mimic psychiatric symptoms is therefore extremely important for accurate diagnosis and effective treatment.

II. NEUROBIOLOGICAL BASIS

The brain operates through a fragile balance of chemicals, electrical signals, and communication networks. Drugs disrupt this balance in sudden and extreme ways, pushing the brain into states very similar to psychiatric disorders. Dopamine, for example, is a chemical involved in pleasure, motivation, and detecting threats. When dopamine levels become too high, the brain becomes overly sensitive to normal stimuli, and ordinary sounds or thoughts may seem threatening or meaningful. This is exactly what happens in both schizophrenia and stimulant intoxication. Serotonin helps regulate mood, perception, and the sense of self. Hallucinogens overstimulate serotonin receptors, causing changes in perception and thinking that closely mirror psychotic or dissociative disorders. Alcohol and benzodiazepines increase GABA, which slows down brain activity; but when the brain becomes dependent on them and then suddenly loses them, it may overreact with panic, anxiety, and agitation. Glutamate, another major chemical involved in learning and memory, is blocked by drugs like ketamine and PCP. When glutamate signaling is disrupted, the brain experiences detachment, confusion, memory gaps, and loss of connection with reality. In essence, drugs force the brain into chemical extremes that are similar to what happens naturally in psychiatric disorders. This explains why drug effects are not random they are biologically predictable and follow the same pathways involved in mental illness.

III. STIMULANTS AND SCHIZOPHRENIA-LIKE PSYCHOSIS

Stimulants like methamphetamine and cocaine strongly activate the brain's reward and motivation pathways by releasing enormous amounts of dopamine. When used repeatedly or in large doses, the brain becomes overstimulated, and this can lead to intense paranoia, suspiciousness, hallucinations, and disorganized behavior. A person may believe that strangers are following them, that conversations on the

street are secret messages directed at them, or that cameras are hidden in their home. These beliefs are not simply irrational they feel intensely real to the person because their brain is interpreting information incorrectly due to chemical overload. Methamphetamine in particular is known to cause tactile hallucinations, such as feeling insects crawling under the skin. When a doctor observes these symptoms, they are nearly identical to what is seen in schizophrenia. Brain imaging studies even show similar patterns of dopamine dysregulation and structural changes (Chen et al., 2020). For some people, stimulant-induced psychosis stops soon after drug use ends, but in others, repeated episodes may trigger long-lasting changes, making the person vulnerable to chronic psychotic disorders. This overlap makes stimulant-related psychosis one of the most challenging drug-induced conditions to diagnose accurately.

IV. COCAINE INTOXICATION AND MANIA-LIKE EPISODES

Cocaine acts rapidly and powerfully on dopamine and norepinephrine systems, which are responsible for energy, alertness, motivation, and emotional intensity. When someone uses cocaine, they may feel extremely confident, energetic, talkative, restless, and unstoppable symptoms that mirror the manic phase of bipolar disorder. They may make impulsive decisions, engage in risky behavior, or spend money recklessly. They may also talk faster than usual and feel as if their thoughts are racing. These symptoms are so similar to bipolar mania that even trained professionals can have difficulty distinguishing between the two conditions. Once the drug wears off, however, the brain undergoes a severe crash. This crash brings sadness, irritability, tiredness, and sometimes suicidal thoughts, closely resembling bipolar depression. The pattern of intense highs followed by deep lows creates a cycle that looks exactly like bipolar disorder. The key difference is that cocaine-induced symptoms are tied directly to drug use and its aftereffects. However, unless clinicians ask detailed questions about timing and drug history, the condition may be mistaken for an emerging mood disorder, leading to misdiagnosis and incorrect long-term treatment (Kalapatapu & Bedi, 2010).

V. CANNABIS AND PSYCHOSIS-SPECTRUM SYMPTOMS

Cannabis affects the brain's endocannabinoid system, which helps regulate mood, memory, thinking, and the processing of rewards. High-potency cannabis strains those with very high THC levels can disrupt this delicate system by overstimulating cannabinoid receptors linked to dopamine release. This can cause changes in perception, thinking, and emotional awareness. People may experience paranoia, such as feeling that others are judging them or plotting against them. Some may develop auditory or visual hallucinations, where they hear whispers or see shadows. Others may feel detached from their surroundings or even question whether their thoughts are being controlled by outside forces. These experiences can resemble early signs of schizophrenia or schizoaffective disorder. Studies show that in people who have a genetic vulnerability such as a family history of psychosis regular cannabis use increases the risk of developing a long-term psychotic disorder (D'Souza et al., 2016). For some, the psychotic symptoms disappear within days or weeks of stopping cannabis, but for others, the symptoms may persist, making it difficult to determine whether cannabis triggered a temporary issue or revealed an underlying disorder.

VI. HALLUCINOGENS AND DISSOCIATIVE OR PSYCHOTIC-LIKE STATES

Hallucinogens such as LSD, psilocybin, and MDMA produce dramatic changes in perception, thought, and emotion by interacting with the serotonin system, particularly the 5-HT2A receptor. These drugs can cause intense sensory experiences, such as seeing vivid colors, patterns, or shapes that are not present. They may also distort time, making minutes feel like hours, or create a sense of detachment from the body. People may believe they have special insight, spiritual awareness, or an altered sense of self. While some individuals view these experiences positively, others may find them frightening or overwhelming. In rare cases, hallucinogen use can lead to Hallucinogen Persisting Perception Disorder (HPPD), in which visual changes and perceptual distortions continue even after the drug has worn off. Dissociative substances like PCP and ketamine act through a

different mechanism blocking NMDA receptors which causes confusion, memory loss, a sense of being outside one's body, and even catatonic behavior. These dissociative episodes can resemble conditions like dissociative identity disorder or catatonic schizophrenia. Because these symptoms can last beyond intoxication, clinicians must carefully differentiate drug effects from primary psychiatric illnesses.

VII. ALCOHOL AND DEPRESSION/ANXIETY-LIKE DISORDERS

Alcohol is one of the most widely used substances that mimics psychiatric disorders because it affects both excitatory and inhibitory systems in the brain. During intoxication, alcohol increases GABA, leading to relaxation, reduced anxiety, and impaired judgment. But with long-term heavy use, the brain reduces its natural GABA production to compensate. When alcohol is suddenly removed, the brain struggles to calm itself, creating a state of hyperarousal. This can lead to intense anxiety, panic attacks, sweating, shaking, restlessness, and rapid heartbeat symptoms that resemble severe anxiety disorders. In addition, alcohol interferes with serotonin and dopamine, two chemicals involved in regulating mood. Over time, this can cause persistent sadness, loss of interest in activities, low energy, and feelings of hopelessness, which look like major depression. Studies have shown that many individuals diagnosed with depression or anxiety are actually experiencing alcohol-related symptoms (Boden & Fergusson, 2011). Because alcohol use is common and often socially accepted, people may not recognize that it is contributing to their emotional struggles.

VIII. BENZODIAZEPINES AND REBOUND ANXIETY

Benzodiazepines, such as diazepam and alprazolam, are commonly used to treat anxiety and insomnia. They work by enhancing the calming effects of GABA, but when taken for long periods, the brain becomes dependent on this external chemical support. The brain gradually reduces its own production of calming signals, meaning that when the benzodiazepine wears off, the person may feel even more anxious than before. This is known as rebound anxiety. Withdrawal from benzodiazepines can be extremely intense, leading to severe panic, fear, muscle tension, insomnia, irritability, shaking, and even hallucinations. These symptoms can be so strong that individuals believe their anxiety disorder has returned or worsened, when in fact the symptoms are caused by dependence and withdrawal. Distinguishing between true anxiety and benzodiazepine withdrawal is essential because the treatment approaches are very different. Long-term benzodiazepine use requires careful tapering to avoid dangerous or distressing withdrawal symptoms. If clinicians do not evaluate substance history, they may assume the patient has chronic anxiety rather than a drug-induced condition.

IX. OPIOIDS AND DEPRESSION-LIKE SYNDROMES

Opioids mimic natural endorphins, the chemicals that create feelings of pleasure and reduce pain. With repeated opioid use, the brain becomes dependent on the external supply and reduces its own production of endorphins. As a result, individuals often experience emotional numbness, lack of motivation, withdrawal from relationships, and inability to feel pleasure symptoms that resemble depression or schizoid personality traits. When opioids are discontinued, the brain is suddenly left without adequate reward signaling, leading to dysphoria (deep emotional discomfort), anxiety, irritability, and suicidal thoughts. These withdrawal symptoms are often mistaken for a major depressive episode. People may feel as though their life has lost all meaning and may misinterpret these symptoms as signs of a permanent psychiatric problem. However, these emotional struggles are directly linked to the brain's altered chemistry from opioid use and withdrawal. Recognizing this distinction is important because treatment for opioid withdrawal differs significantly from treatment for clinical depression. Without proper diagnosis, individuals may receive inappropriate medications instead of necessary addiction treatment.

X. CLINICAL IMPLICATIONS

Drug-induced psychopathologies create significant clinical challenges because their symptoms closely resemble primary psychiatric disorders. The overlap is so strong that even experienced clinicians may initially

misinterpret stimulant-induced psychosis as schizophrenia, cocaine euphoria as bipolar mania, or alcohol withdrawal panic as an anxiety disorder. This similarity makes it essential for mental health professionals to conduct thorough, systematic evaluations before assigning a long-term psychiatric diagnosis. A key implication is the importance of establishing a clear temporal relationship between substance use and symptom onset. Clinicians must ask detailed questions about when the symptoms began, whether they appeared during intoxication or withdrawal, and whether they improved after a period of abstinence. Without this timeline, misdiagnosis is highly likely. In addition, many patients minimize or deny substance use due to stigma or fear of legal consequences, so obtaining collateral information from family members or caregivers becomes necessary for an accurate diagnosis.

Another major implication is the need for routine toxicology screening in emergency psychiatric settings. Because drug-induced symptoms can be severe, misleading, or even life-threatening, objective evidence of recent substance use provides valuable diagnostic clarity. However, clinicians must also remember that drugs with long half-lives, like cannabis, may appear on tests long after intoxication but symptoms may not necessarily be ongoing. Therefore, toxicology results must be interpreted carefully alongside clinical history rather than used in isolation. Additionally, symptoms should be re-evaluated after 2 to 4 weeks of abstinence, as DSM-5-TR suggests. If symptoms decrease significantly, the condition is likely substance-induced; if symptoms persist, a primary psychiatric disorder may be present. This observation period prevents premature and potentially harmful treatment decisions.

Equally important is avoiding unnecessary long-term psychiatric medication. For example, stimulant-induced psychosis may resolve completely once the individual stops the drug, yet patients may be incorrectly placed on lifelong antipsychotic treatment if clinicians do not reassess symptoms after abstinence. Similarly, cocaine-induced mania or alcohol-related depression should not lead to immediate labeling as bipolar disorder or major depressive disorder. Misdiagnosis not only exposes patients to unnecessary medications but also prevents them from receiving appropriate addiction-focused interventions, such as detoxification, relapse-prevention therapy, motivational interviewing, harm-reduction strategies, or medication-assisted treatment.

Another clinical implication is the need for integrated care, where substance use treatment and mental health treatment occur simultaneously. Many individuals experience both psychological distress and drug use at the same time, and separating the two can be artificial and counterproductive. Clinicians should also be aware that drug-induced episodes may act as early warning signs in vulnerable individuals. For example, cannabis-induced psychosis in a teenager may signal an underlying genetic susceptibility to schizophrenia. This requires careful monitoring, psychoeducation for the family, early intervention, and long-term risk management.

Finally, clinicians must engage in nonjudgmental communication. Many patients fear being blamed or labeled as “addicts,” which prevents honest discussion about drug use. Creating a safe therapeutic environment encourages transparency and improves diagnostic accuracy. In summary, the major clinical implications highlight the need for careful assessment, avoidance of premature diagnoses, integrated treatment planning, and continuous monitoring to differentiate drug-induced states from primary psychiatric illnesses.

XI. CONCLUSION

Drug-induced psychopathologies demonstrate how profoundly psychoactive substances can alter the brain’s functioning and how closely these artificially induced states resemble genuine psychiatric disorders. The fact that drugs can reproduce symptoms such as hallucinations, mania, severe depression, panic attacks, or dissociation shows that mental states are deeply rooted in neurobiology and can be shifted dramatically by chemical changes. Recognizing this overlap is crucial not only for accurate diagnosis but also for developing a more compassionate understanding of both substance use and mental illness. Rather than viewing drug effects as purely behavioral choices, this perspective highlights the brain’s vulnerability and the delicate nature of its chemical balance.

The science behind these conditions reveals that psychoactive substances do not produce random effects; they trigger predictable patterns based on the

neural circuits they target. Stimulants push dopamine to extreme levels, creating paranoia and psychosis similar to schizophrenia. Cocaine creates powerful mood swings comparable to bipolar disorder. Cannabis destabilizes the endocannabinoid system, producing paranoia and hallucinations in susceptible individuals. Hallucinogens disrupt serotonin pathways, creating experiences that mimic dissociation or psychosis. Alcohol and benzodiazepines suppress the brain's calming system, causing anxiety and depression during withdrawal. Opioids silence natural reward pathways, leading to anhedonia and emotional numbness identical to major depression. These similarities reinforce the idea that many psychiatric symptoms, whether drug-induced or naturally occurring, emerge from the same biological foundations.

Clinically, the distinction between drug-induced and primary psychiatric disorders is essential because the treatment, prognosis, and long-term risks differ significantly. A person with stimulant-induced psychosis may recover fully after sobriety, while someone with schizophrenia requires long-term antipsychotic care. A person with alcohol-induced anxiety may improve with detoxification, while someone with generalized anxiety disorder needs structured psychotherapy and medication management. Without accurate differentiation, individuals may receive the wrong treatment and continue to suffer unnecessarily. Therefore, clinicians must prioritize careful diagnostic procedures, ongoing observation, and comprehensive assessment strategies.

From a broader perspective, the study of drug-induced psychopathology offers valuable insight into the biological basis of mental conditions. By observing how certain substances induce specific psychiatric symptoms, researchers can better understand the neurotransmitter systems involved in disorders like schizophrenia, bipolar disorder, depression, and anxiety. These insights may guide future treatments and improve early detection strategies. Additionally, educating the public about how drugs affect mental health can reduce stigma, encourage early help-seeking, and prevent long-term harm.

In conclusion, drug-induced psychopathologies underscore the powerful connection between neurochemistry and mental health. They highlight the need for careful clinical evaluation, informed diagnostic reasoning, integrated substance use treatment, and continued scientific research. Understanding the overlap between drug effects and psychiatric symptoms strengthens our ability to provide accurate, effective, and compassionate care to those experiencing psychological distress whether due to substances, mental illness, or both.

REFERENCES

[1] American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.; DSM-5-TR). American Psychiatric Association.

[2] Amato, L., Minozzi, S., Pani, P. P., & Davoli, M. (2010). Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, 2010(2), CD003409.

[3] Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ, 325(7374), 1212–1213.

[4] Ashton, H. (2005). The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry, 18(3), 249–255.

[5] Basu, A., & Chadda, R. K. (2020). Substance-induced psychosis: A clinical update. Indian Journal of Psychiatry, 62(3), 283–292.

[6] Becker, H. C. (2014). Alcohol dependence, withdrawal, and relapse. In K. K. Patel (Ed.), Handbook of Clinical Neurology (Vol. 125, pp. 139–171). Elsevier.

[7] Boden, J. M., & Fergusson, D. M. (2011). Alcohol and depression. Addiction, 106(5), 906–914. https://doi.org/10.1111/j.1360-0443.2010.03351.x

[8] Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E. M., & Franck, J. (2012). Amphetamine-induced psychosis a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry, 12, 221.

[9] Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344.

[10] Caton, C. L., Samet, S., & Hasin, D. S. (2000). When acute-stage psychosis and substance use co-occur: Differentiating substance-induced and primary psychotic disorders. Journal of Psychiatric Practice, 6(5), 256–266.

[11] Chen, C. K., Lin, S. K., Sham, P. C., Ball, D., Loh, E. W., Hsiao, C. C., & Murray, R. M. (2020). Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine, 33(8), 1407–1414.

[12] D'Souza, D. C., Radhakrishnan, R., Sherif, M., Cortes-Briones, J., Cahill, J., Gupta, S., & Skosnik, P. (2016). Cannabinoids and psychosis: Disentangling the signal from the noise. Biological Psychiatry, 79(7), 514–522.

[13] Fornito, A., Zalesky, A., & Breakspear, M. (2015). The connectomics of brain disorders. Nature Reviews Neuroscience, 16(3), 159–172.

[14] Gable, R. S. (1993). Towards a comparative overview of dependence potential and acute toxicity of psychoactive substances used non-medically. Psychopharmacology, 111(1), 1–11.

[15] Gilman, J. M., Ramchandani, V. A., Davis, M. B., Bjork, J. M., & Hommer, D. W. (2008). Why we drink: A functional magnetic resonance imaging study of alcohol intoxication in social drinkers. Biological Psychiatry, 64(7), 557–555.

[16] Halpern, J. H., & Pope, H. G. (2003). Hallucinogen persisting perception disorder: What do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109–119.

[17] Iwanami, A., Sugiyama, A., Kuroki, N., Une, H., Okajima, Y., Sato, T., & Kaneko, T. (1994). Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan: A preliminary report. Acta Psychiatrica Scandinavica, 89(6), 428–432.

[18] Kalapatapu, R. K., & Bedi, G. (2010). Clinical overview of stimulant-induced mania. International Review of Psychiatry, 22(5), 445–455.

[19] Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry, 3(8), 760–773.

[20] Koob, G. F., Buck, C. L., Cohen, A., Edwards, S., Park, P. E., Schlosburg, J. E., … & Vendruscolo, L. F. (2014). Addiction as a stress surfeit disorder. Neuropharmacology, 76(Part B), 370–382.

[21] Kosten, T. R., & George, T. P. (2002). The neurobiology of opioid dependence: Implications for treatment. Science & Practice Perspectives, 1(1), 13–20.

[22] Kushner, M. G., Abrams, K., & Borchardt, C. (2000). The relationship between anxiety disorders and alcohol use disorders: A review of major perspectives and findings. Clinical Psychology Review, 20(2), 149–171.

[23] Lader, M. (2011). Benzodiazepines revisited—will we ever learn? Addiction, 106(12), 2086–2109.

[24] Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M. C., Lorusso, M., & di Giannantonio, M. (2018). Hallucinogen Persisting Perception Disorder (HPPD): Etiology, clinical features, and therapeutic perspectives. Brain Sciences, 8(3), 47.

[25] Murray, R. M., Englund, A., Abi-Dargham, A., Lewis, D. A., Di Forti, M., Davies, C., & McGuire, P. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89–104.

[26] Nestler, E. J. (2014). Cellular basis of memory for addiction. Dialogues in Clinical Neuroscience, 16(4), 431–443.

[27] Rickels, K., Schweizer, E., Case, W. G., & Greenblatt, D. J. (1990). Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Archives of General Psychiatry, 47(10), 908–915.

[28] Roberts, C. A., Jones, A., & Montgomery, C. (2019). Cannabis use and the working memory system: A meta-analysis. Psychopharmacology, 236(6), 1899–1919.

[29] Sato, M. (1992). A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Annals of the New York Academy of Sciences, 654(1), 160–170.

[30] Schuckit, M. A. (2016). Treatment of opioid-use disorders. New England Journal of Medicine, 375(4), 357–368.

[31] Volkow, N. D., & Boyle, M. (2018). Neuroscience of addiction: Relevance to prevention and treatment. American Journal of Psychiatry, 175(8), 729–740.

[32] Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019). Prevention and treatment of opioid misuse and addiction: A review. JAMA Psychiatry, 76(2), 208–216.

[33] Volkow, N. D., Swanson, J. M., Evins, A. E., De Lisi, L. E., Meier, M. H., Gonzalez, R., … & Baler, R. (2016). Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A review. JAMA Psychiatry, 73(3), 292–297.